ARCHIVES

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

This article is from The Cancer Letter archive.

Vol. 03 No. 40 | October 7, 1977

Download PDF Visit The Full Archive

Related Articles

Straus asks to “Set Record Straight”

September 2, 1988

NIH On R29 Phase-Out; Grant Review Appeals Process Changed

January 23, 1998

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

FDA Roundup: Public Citizen Uses Logic of FDA’s Critical Path to Challenge Decision On Anti-Obesity Drug.

June 9, 2006

National Cancer Policy Forum Studies Modernization, Funding Of Cooperative Group Program.

July 11, 2008

Funding Opportunities.

March 22, 2002